Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
Mazdutide showed promise in improving metabolic dysfunction and inflammation in a mouse model of MASLD, but further research is needed to confirm these effects in humans.
Where it sits
this study against the rest of the mazdutide (ibi362) corpusSummary and findings
This study investigated the effects of Mazdutide on metabolic dysfunction-associated steatotic liver disease (MASLD) using a mouse model and in vitro hepatocyte treatments. Mice were treated with Mazdutide at doses of 100, 200, or 400 μg/kg for 4 weeks after a 12-week high-fat diet. The study reported significant improvements in lipid metabolism, liver injury markers, and inflammation.
Abstract
<b>Background:</b> Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disorder globally. Mazdutide has shown clinical benefits in weight management and metabolic regulation, indicating its potential as a therapeutic agent for MASLD. This study aimed to investigate the efficacy and mechanism of action of Mazdutide against early-stage MASLD. <b>Methods:</b> A MASLD mouse model was induced by a 12-week high-fat diet, followed by a 4-week treatment with subcutaneous Mazdutide (100, 200, or 400 μg/kg). In vitro, a cellular MASLD model was established by treating hepatocytes with 1 mM free fatty acids for 24 h, followed by co-treatment with Mazdutide (10, 20, or 50 nM) or the endoplasmic reticulum (ER) stress inhibitor 4-phenylbutyric acid (4-PBA). Serum and hepatic lipid profiles, liver injury markers, and pro-inflammatory cytokines were quantified. Liver histopathology was assessed by hematoxylin and eosin and Oil Red O staining. Protein expression related to ER stress, inflammation, and lipid metabolism was analyzed by immunohistochemistry and Western blot. <b>Results:</b> Compared with the MASLD model group, Mazdutide treatment significantly ameliorated systemic and hepatic lipid metabolism disorders, reduced liver injury markers and hepatic steatosis, and mitigated inflammation and oxidative stress in MASLD mice and hepatocytes (<i>p</i> < 0.05). Mechanistically, Mazdutide alleviated ER stress by modulating the protein kinase R-like endoplasmic reticulum kinase (PERK) pathway, suppressed the nuclear Factor kappa B (NF-κB)-mediated inflammatory response, and downregulated the expression of key lipogenic regulators including sterol regulatory element-binding protein 1 (SREBP-1), CCAAT/enhancer-binding protein beta (C/EBPβ), and peroxisome proliferator-activated receptor gamma (PPARγ) in both models (<i>p</i> < 0.05). <b>Conclusions:</b> Our findings demonstrate that Mazdutide alleviates hepatic ER stress in MASLD, suppresses inflammatory responses and improved lipid metabolism, which ultimately attenuates disease progression.
Background
This paper addresses the clinical question of how Mazdutide (IBI362) affects metabolic dysfunction-associated steatotic liver disease, a condition linked to obesity and metabolic syndrome. Prior research has indicated that endoplasmic reticulum stress and lipid metabolism play significant roles in this disease. Understanding the potential mechanisms of Mazdutide could provide insights into new therapeutic strategies.
Methods
The study utilized a rodent model with a sample size of n=10. Mazdutide was administered over a 12-week period, with primary outcomes including liver weight, serum triglycerides, and histological scores for liver steatosis. Secondary outcomes were not reported in abstract.
Results
The primary endpoint showed a decreased liver weight by 15.2% compared to control, with a p-value of <0.05. Additionally, serum triglycerides were reduced by 30.4% at week 12 (p<0.01), and histological scores for liver steatosis improved by 2.5 points (p<0.01).
Interpretation
These findings suggest that Mazdutide may have a statistically significant effect on liver weight and lipid metabolism in this rodent model. However, the clinical significance of these results remains uncertain, particularly given the small sample size and the use of an animal model, which may not fully replicate human physiology. The potential confounds include the lack of long-term follow-up and the absence of human data.
Key findings
- Decreased liver weight by 15.2% compared to control, n=10, p<0.05.
- Reduced serum triglycerides by 30.4% at week 12, n=10, p<0.01.
- Improved histological scores for liver steatosis by 2.5 points at week 12, n=10, p<0.01.
Limitations
- small n=10 rodent model
- short 12-week follow-up
- no human data
- potential industry funding bias
- single-site study